Actively Recruiting
A Predictive Model for Recurrence of Colorectal Cancer Based on Multi-omics of Portal Vein Blood
Led by Peking University Shougang Hospital · Updated on 2024-07-31
350
Participants Needed
1
Research Sites
360 weeks
Total Duration
On this page
Sponsors
P
Peking University Shougang Hospital
Lead Sponsor
B
Beijing Tiantan Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
This multi-center study aims to develop a precise predictive model for colorectal cancer (CRC) recurrence and metastasis based on multi-omics analysis of portal vein blood. Despite advances in surgical treatments, approximately 40% of CRC patients experience tumor recurrence or metastasis post-surgery, with 80-90% of metastases being unresectable. The study will include stage I-IV CRC patients and will be conducted in two phases: a nested case-control study and a bidirectional cohort study. Comprehensive multi-omics sequencing will be performed on samples from primary tumors, adjacent tissues, normal intestinal tissues, portal vein blood, and peripheral blood. The goal is to identify specific biomarkers in the portal vein and peripheral blood associated with CRC recurrence and metastasis, and to compare the predictive accuracy of models based on these biomarkers. The ultimate objective is to provide a more effective method for early prediction and intervention of CRC recurrence and metastasis, thereby improving patient outcomes. Project Information: Project Title: A predictive model for recurrence of colorectal cancer based on multi-omics of portal vein blood: a multi-center study Project Duration: January 2020 to December 2026 Lead Institution: Peking University Shougang Hospital Principal Investigator: Gu Jin Contact: Hong Haopeng, 18059211195@163.com
CONDITIONS
Official Title
A Predictive Model for Recurrence of Colorectal Cancer Based on Multi-omics of Portal Vein Blood
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Histologically confirmed stage I-IV colorectal cancer (CRC)
- Availability of pre-operative and intra-operative blood samples (portal vein and peripheral blood) and primary tumor tissue samples
- No neoadjuvant therapy before surgery
You will not qualify if you...
- Prior history of other malignancies
- Incomplete clinical information or pathology reports
- Incomplete follow-up records
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University Shougang Hospital
Beijing, Beijing Municipality, China, 100144
Actively Recruiting
Research Team
D
Dandan Huang, M.D
CONTACT
H
Haopeng Hong, Ph.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here